摘要
迪诺单抗是目前欧美国家对有高骨折风险、经其他药物治疗失败或耐受的绝经后骨质疏松症女性推荐用药。本文对近年关于迪诺单抗对绝经后骨质疏松症患者骨密度、骨折发生率、依从性、不良事件发生率等研究进展做一综述。
Denosumab is indicated for postmenopausal osteoporosis women with high fracture risk , other drug treatment failure or intolerance of recommended drug use in Western countries .A large number of clinical trials have been conducted about Denosumab effects on bone mineral density （BMD）, fracture incidence, compliance, as well as the ad-verse events .This article make a review of the progress .
出处
《中华骨质疏松和骨矿盐疾病杂志》
2015年第1期74-77,共4页
Chinese Journal Of Osteoporosis And Bone Mineral Research
